RESP  |  Translational Research in Respiratory Diseases Program

A $109M fund aims to mitigate impact of the pandemic on care delivery in Canada and beyond, as well as contribute to better understanding of the disease

A new study shows that rifampin regimen is cheaper than isoniazid for latent tuberculosis

A new study highlights a strong risk factor for COPD related to lung development

RI-MUHC researchers awarded MUHC Foundation funding for a second round of projects with potential impact in a short timeframe

Researchers, advocates and patients gather on Rare Disease Research Day at the RI-MUHC

GCCR group develops worldwide survey on smell loss

RI-MUHC researchers awarded MUHC Foundation funding for projects with potential impact in a short timeframe

RI-MUHC researchers take leading roles in the initiative

Clinical research educational training program benefits researchers, staff and students at the inaugural event

“With science under attack, scientists have little choice but to step into the limelight and fight for what matters most” – Dr. Madhukar Pai

The RI-MUHC is one of eight research centres participating in an NIH-funded project to accelerate the understanding of rare suppurative respiratory diseases and innovate in the field

World-renowned researchers. Vibrant learning environment. First-class facilities. If it sounds too good to be true, you weren’t at the Open House!

“The greatest achievement is seen in the people we train,” says director of the McConnell Centre for Innovative Medicine

Congratulations to RI-MUHC researchers who received Foundation awards, scholarships and grants!

Leveraging discovery to improve human health “Across the Lifespan”

Delegation takes part in a working visit to the Helmholtz Centre for Infection Research (HZI)

Inductees are honoured for leadership in the health sciences

Interview with Carolyn Baglole, director of the new McGill Research Centre for Cannabis

Congratulations to students who contributed to the scientific life of our institute this summer!

Study aims to lighten the burden of persistent infections in people living with cystic fibrosis